Germany Pharmaceuticals Market
Segments - by Drug Classes (Anti-Cancer, Anti-diabetics, Anti-rheumatics, Vaccines, Anti-viral, Immunosuppressants, Bronchodilators, Dermatological, Anti-hypertensive, and Others), Applications (Oncology [Breast Cancer, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, and Others], Infectious Diseases, Cardiovascular Diseases, Central Nervous System Disorders, Immunological Disorders, Metabolic Disorders, Gastrointestinal Disorders, Respiratory Diseases, Ophthalmology, Dermatology Disorders, and Others), Types (Branded and Generics), and Formulations (Solid Formulation [Tablets, Capsules, and Others] and Liquid & Semi-Liquid Formulation [Oral, Topical, Sublingual & buccal, Rectal, and Parenteral]) - Germany Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The Germany Pharmaceuticals market size was valued at USD 44.1 billion in 2020 and is anticipated to expand at a CAGR of 5.9% during the forecast period, 2021-2028. The growth of the market is attributed to the rising patent applications which are focused on the determination of the latest drug delivery systems, formulations, and new drugs. The European Patent Office or the EPO Patent Index of 2019 shows that the number of patent applications has risen by 4.3% in 2018 in this pharmaceutical field.
Pharmaceutical organizations discover, produce, develop and market pharmaceutical drugs for usage as medications that can be self-administered to all patients, which can vaccinate them, alleviate their symptoms, and cure them with proper diagnosis and treatment. These firms can deal in brand or generic medical devices and medications. They have their own subject to regulations and laws that govern the testing, efficacy, marketing, safety, and patenting of drugs.
The research and development tasks that these firms are operational upon include a wide variety of activities from introductory & basic research to late-stage development involving genetic engineering, assay development, efficacy & safety tests in animal models, clinical trials that involves humans, target validation, and lead optimization plus hit exploration using candidates as a service.
According to the WHO report survey of 2020, the cost of research every pharmaceutical firm undertakes ranges from one billion for every individual project ranging to various activities such as marketing, financing, patenting, and supply chain. The COVID-19 pandemic made a significant impact on the pharmaceutical market, including Germany, owing to the social distancing and restrictions involving travel disrupting supply chains to transport drugs to other countries or even within Germany.
However, the shift began when the hospital, government authorities, and administration bodies decided to increase their investments and funding to the pharmaceutical firms to focus their activities on the coronavirus vaccine. This benefitted the pharmaceutical industry as they had access to and played a crucial role in the supply chain management of the vaccination. This along with the further investment by the pharmaceutical & biotech firms in artificial intelligence & machine learning becomes a major reason for the boosting of the pharmaceutical market.
Market Trends, Drivers, Restraints, and Opportunities
- An increase in spending and investment in research and development activities is the primary reason for the projection for boosting the German pharmaceuticals market growth during the forecast period, 2021-2028.
- There have been significant changes in the drug approval process by their respective regional administration bodies, making it more lenient and swift. In the United States, the Century Cures bill was passed on the primary notion of increasing the pace of the launch of medical devices and breakthrough drugs. These modifications in the approval processes are major factors boosting the German pharmaceuticals market growth.
- High prices for the development of drugs, diagnosis, and treatments and high cost & maintenance of services from the company’s perspective are anticipated to hinder the German pharmaceuticals market growth. This becomes extremely difficult to function in developing countries such as India, South Africa, and Brazil where there is limited healthcare infrastructure that the pharmaceutical companies can leverage.
- Lack of standardization in the biotechnology & pharmaceutical firms does not necessarily comply with international regulatory requirements can lead to quality issues and thereby can present as main challenges that can restrict the market expansion in the coming years.
- R&D investment and technological advancement are expected to offer significant opportunities for the market players. Researchers and scientists have now discovered advanced diagnostic techniques such as customized care that can shorten any product’s life cycle which can thereby lead to the rapid development of the latest drug products and derivatives.
Scope of the Report
The report on the German pharmaceuticals market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Pharmaceuticals Market - Germany Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Drug Classes (Anti-Cancer, Anti-diabetics, Anti-rheumatics, Vaccines, Anti-viral, Immunosuppressants, Bronchodilators, Dermatological, Anti-hypertensive, and Others), Applications (Oncology [Breast Cancer, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, and Others], Infectious Diseases, Cardiovascular Diseases, Central Nervous System Disorders, Immunological Disorders, Metabolic Disorders, Gastrointestinal Disorders, Respiratory Diseases, Ophthalmology, Dermatology Disorders, and Others), Types (Branded and Generics), and Formulations (Solid Formulation [Tablets, Capsules, and Others] and Liquid & Semi-Liquid Formulation [Oral, Topical, Sublingual & buccal, Rectal, and Parenteral]) |
|
Regional Scope |
Germany |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Boehringer Ingelheim International GmbH; Bayer AG; Merck & Co Inc; Fresenius Kabi AG; STADA Arzneimittel AG; Pfizer Inc; Abbott Laboratories; Abbvie Inc; Teva Pharmaceuticals Industries Ltd; and Novartis AG |
Germany Pharmaceuticals Market Segment Insights
Anti-cancer segment is projected to represent a large market share
Based on drug classes, the Germany pharmaceuticals market is divided into anti-cancer, anti-diabetics, anti-rheumatics, vaccines, anti-viral, immunosuppressants, bronchodilators, dermatological, anti-hypertensive, and others. The anti-cancer segment is expected to constitute a major share of 15.5% of the market during the forecast years, 2021-2028 owing to the increase in merger & acquisition activities with respect to the constant change of regular protocols.
There has also been a significant development on the activities which fall under the anti-cancer segment including the treatment of different viruses that can cause cancer. Recently the studies have been shifting towards the coronavirus , as German scientists were the first ones to patent the paper upon how the coronavirus can severely affect cancer patient. This improved the research activities holding upon the anti-cancer segment.
Oncology segment is anticipated to register a major market share
On the basis of applications, the Germany pharmaceuticals market is segmented into oncology, infectious diseases, cardiovascular diseases, central nervous system disorders, immunological disorders, metabolic disorders, gastrointestinal disorders, respiratory diseases, ophthalmology, dermatology disorders, and others.
The oncology segment is further segmented into breast cancer, lung cancer, colorectal cancer, ovarian cancer, prostate cancer, and others. The oncology segment is expected to constitute a major share of 15.4% of the market during the forecast years, 2021-2028 owing to the increase in strategic initiatives and projects such as partnerships, development, collaboration and strengthening of the portfolio. Organizations have also developed new methods for various problems within the oncology study itself, owing to the increasing prevalence of these diseases.
Branded segment is estimated to reach the largest market share
On the basis of types, the Germany pharmaceuticals market is bifurcated into branded and generics. The branded segment is expected to constitute a major share of 15.4% of the market during the forecast years, 2021-2028 owing to the increasing adaption of latest therapies, along with the strategic partnerships which drive the wide-scale penetration of branded drugs.
The introduction of biosimilars has announced a major shift in various cancer treatments in Germany. This was a follow through study from the branded drugs perspective when biosimilars were introduced.
Solid Formulation segment is expected to account for the largest market share
Based on formulations, the Germany pharmaceuticals market is bifurcated into solid formulation and liquid & semi-liquid formulation. The solid formulation segment is further segmented into tablets, capsules, and others. The liquid & semi-liquid formulation segment is further segmented into oral, topical, sublingual & buccal, rectal, and parenteral.
The solid formulation segment is expected to register a significant CAGR during the forecast years, 2021-2028 owing to the several benefits including cost-effectiveness with respect to their cost. The administrative bodies of the pharmaceutical organizations have been focusing upon new strategic initiatives to expand their presence outside Germany, and with the solid formulation.
Segments
Segments Covered in the ReportThe Germany pharmaceuticals market size has been segmented in terms of
Drug Classes
- Anti-Cancer
- Anti-diabetics
- Anti-rheumatics
- Vaccines
- Anti-viral
- Immunosuppressants
- Bronchodilators
- Dermatological
- Anti-hypertensive
- Others
- Oncology
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Ovarian Cancer
- Prostate Cancer
- Others
- Infectious Diseases
- Cardiovascular Diseases
- Central Nervous System Disorders
- Immunological Disorders
- Metabolic Disorders
- Gastrointestinal Disorders
- Respiratory Diseases
- Ophthalmology
- Dermatology Disorders
- Others
- Branded
- Generics
- Solid Formulation
- Tablets
- Capsules
- Others
- Liquid & Semi-Liquid Formulation
- Oral
- Topical
- Sublingual & buccal
- Rectal
- Parenteral
- Boehringer Ingelheim International GmbH
- Bayer AG
- Merck & Co Inc
- Fresenius Kabi AG
- STADA Arzneimittel AG
- Pfizer Inc
- Abbott Laboratories
- Abbvie Inc
- Teva Pharmaceuticals Industries Ltd
- Novartis AG
Competitive Landscape
Major players competing in the Germany pharmaceuticals market are Boehringer Ingelheim International GmbH; Bayer AG; Merck & Co Inc; Fresenius Kabi AG; STADA Arzneimittel AG; Pfizer Inc; Abbott Laboratories; Abbvie Inc; Teva Pharmaceuticals Industries Ltd; and Novartis AG. These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For example, Merck & Co Inc signed a collaboration project with Dohme Corporation for the Ebola and COVID vaccinations for the entire distribution across Germany and have been approved by the European Union.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pharmaceuticals Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pharmaceuticals Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pharmaceuticals Market - Supply Chain
4.5. Global Pharmaceuticals Market Forecast
4.5.1. Pharmaceuticals Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pharmaceuticals Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Pharmaceuticals Market Absolute $ Opportunity
5. Global Pharmaceuticals Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Pharmaceuticals Market Size and Volume Forecast by Types
5.3.1. Branded
5.3.2. Generics
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Pharmaceuticals Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Pharmaceuticals Market Size and Volume Forecast by Applications
6.3.1. Oncology
6.3.2. Breast Cancer
6.3.3. Lung Cancer
6.3.4. Colorectal Cancer
6.3.5. Ovarian Cancer
6.3.6. Prostate Cancer
6.3.7. Others
6.3.8. Infectious Diseases
6.3.9. Cardiovascular Diseases
6.3.10. Central Nervous System Disorders
6.3.11. Immunolo
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Pharmaceuticals Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Pharmaceuticals Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Pharmaceuticals Demand Share Forecast, 2019-2026
8. North America Pharmaceuticals Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Pharmaceuticals Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Pharmaceuticals Market Size and Volume Forecast by Types
8.4.1. Branded
8.4.2. Generics
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Pharmaceuticals Market Size and Volume Forecast by Applications
8.7.1. Oncology
8.7.2. Breast Cancer
8.7.3. Lung Cancer
8.7.4. Colorectal Cancer
8.7.5. Ovarian Cancer
8.7.6. Prostate Cancer
8.7.7. Others
8.7.8. Infectious Diseases
8.7.9. Cardiovascular Diseases
8.7.10. Central Nervous System Disorders
8.7.11. Immunolo
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Pharmaceuticals Demand Share Forecast, 2019-2026
9. Latin America Pharmaceuticals Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Pharmaceuticals Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Pharmaceuticals Market Size and Volume Forecast by Types
9.4.1. Branded
9.4.2. Generics
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Pharmaceuticals Market Size and Volume Forecast by Applications
9.7.1. Oncology
9.7.2. Breast Cancer
9.7.3. Lung Cancer
9.7.4. Colorectal Cancer
9.7.5. Ovarian Cancer
9.7.6. Prostate Cancer
9.7.7. Others
9.7.8. Infectious Diseases
9.7.9. Cardiovascular Diseases
9.7.10. Central Nervous System Disorders
9.7.11. Immunolo
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Pharmaceuticals Demand Share Forecast, 2019-2026
10. Europe Pharmaceuticals Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Pharmaceuticals Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Pharmaceuticals Market Size and Volume Forecast by Types
10.4.1. Branded
10.4.2. Generics
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Pharmaceuticals Market Size and Volume Forecast by Applications
10.7.1. Oncology
10.7.2. Breast Cancer
10.7.3. Lung Cancer
10.7.4. Colorectal Cancer
10.7.5. Ovarian Cancer
10.7.6. Prostate Cancer
10.7.7. Others
10.7.8. Infectious Diseases
10.7.9. Cardiovascular Diseases
10.7.10. Central Nervous System Disorders
10.7.11. Immunolo
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Pharmaceuticals Demand Share Forecast, 2019-2026
11. Asia Pacific Pharmaceuticals Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Pharmaceuticals Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Pharmaceuticals Market Size and Volume Forecast by Types
11.4.1. Branded
11.4.2. Generics
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Pharmaceuticals Market Size and Volume Forecast by Applications
11.7.1. Oncology
11.7.2. Breast Cancer
11.7.3. Lung Cancer
11.7.4. Colorectal Cancer
11.7.5. Ovarian Cancer
11.7.6. Prostate Cancer
11.7.7. Others
11.7.8. Infectious Diseases
11.7.9. Cardiovascular Diseases
11.7.10. Central Nervous System Disorders
11.7.11. Immunolo
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Pharmaceuticals Demand Share Forecast, 2019-2026
12. Middle East & Africa Pharmaceuticals Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Pharmaceuticals Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Pharmaceuticals Market Size and Volume Forecast by Types
12.4.1. Branded
12.4.2. Generics
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Pharmaceuticals Market Size and Volume Forecast by Applications
12.7.1. Oncology
12.7.2. Breast Cancer
12.7.3. Lung Cancer
12.7.4. Colorectal Cancer
12.7.5. Ovarian Cancer
12.7.6. Prostate Cancer
12.7.7. Others
12.7.8. Infectious Diseases
12.7.9. Cardiovascular Diseases
12.7.10. Central Nervous System Disorders
12.7.11. Immunolo
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Pharmaceuticals Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Pharmaceuticals Market: Market Share Analysis
13.2. Pharmaceuticals Distributors and Customers
13.3. Pharmaceuticals Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Boehringer Ingelheim International GmbH
13.4.2. Bayer AG
13.4.3. Merck & Co Inc
13.4.4. Fresenius Kabi AG
13.4.5. STADA Arzneimittel AG
13.4.6. Pfizer Inc
13.4.7. Abbott Laboratories
13.4.8. Abbvie Inc
13.4.9. Teva Pharmaceuticals Industries Ltd
13.4.10. Novartis AG
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pharmaceuticals Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pharmaceuticals Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pharmaceuticals Market - Supply Chain
4.5. Global Pharmaceuticals Market Forecast
4.5.1. Pharmaceuticals Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pharmaceuticals Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Pharmaceuticals Market Absolute $ Opportunity
5. Global Pharmaceuticals Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Pharmaceuticals Market Size and Volume Forecast by Types
5.3.1. Branded
5.3.2. Generics
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Pharmaceuticals Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Pharmaceuticals Market Size and Volume Forecast by Applications
6.3.1. Oncology
6.3.2. Breast Cancer
6.3.3. Lung Cancer
6.3.4. Colorectal Cancer
6.3.5. Ovarian Cancer
6.3.6. Prostate Cancer
6.3.7. Others
6.3.8. Infectious Diseases
6.3.9. Cardiovascular Diseases
6.3.10. Central Nervous System Disorders
6.3.11. Immunolo
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Pharmaceuticals Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Pharmaceuticals Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Pharmaceuticals Demand Share Forecast, 2019-2026
8. North America Pharmaceuticals Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Pharmaceuticals Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Pharmaceuticals Market Size and Volume Forecast by Types
8.4.1. Branded
8.4.2. Generics
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Pharmaceuticals Market Size and Volume Forecast by Applications
8.7.1. Oncology
8.7.2. Breast Cancer
8.7.3. Lung Cancer
8.7.4. Colorectal Cancer
8.7.5. Ovarian Cancer
8.7.6. Prostate Cancer
8.7.7. Others
8.7.8. Infectious Diseases
8.7.9. Cardiovascular Diseases
8.7.10. Central Nervous System Disorders
8.7.11. Immunolo
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Pharmaceuticals Demand Share Forecast, 2019-2026
9. Latin America Pharmaceuticals Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Pharmaceuticals Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Pharmaceuticals Market Size and Volume Forecast by Types
9.4.1. Branded
9.4.2. Generics
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Pharmaceuticals Market Size and Volume Forecast by Applications
9.7.1. Oncology
9.7.2. Breast Cancer
9.7.3. Lung Cancer
9.7.4. Colorectal Cancer
9.7.5. Ovarian Cancer
9.7.6. Prostate Cancer
9.7.7. Others
9.7.8. Infectious Diseases
9.7.9. Cardiovascular Diseases
9.7.10. Central Nervous System Disorders
9.7.11. Immunolo
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Pharmaceuticals Demand Share Forecast, 2019-2026
10. Europe Pharmaceuticals Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Pharmaceuticals Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Pharmaceuticals Market Size and Volume Forecast by Types
10.4.1. Branded
10.4.2. Generics
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Pharmaceuticals Market Size and Volume Forecast by Applications
10.7.1. Oncology
10.7.2. Breast Cancer
10.7.3. Lung Cancer
10.7.4. Colorectal Cancer
10.7.5. Ovarian Cancer
10.7.6. Prostate Cancer
10.7.7. Others
10.7.8. Infectious Diseases
10.7.9. Cardiovascular Diseases
10.7.10. Central Nervous System Disorders
10.7.11. Immunolo
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Pharmaceuticals Demand Share Forecast, 2019-2026
11. Asia Pacific Pharmaceuticals Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Pharmaceuticals Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Pharmaceuticals Market Size and Volume Forecast by Types
11.4.1. Branded
11.4.2. Generics
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Pharmaceuticals Market Size and Volume Forecast by Applications
11.7.1. Oncology
11.7.2. Breast Cancer
11.7.3. Lung Cancer
11.7.4. Colorectal Cancer
11.7.5. Ovarian Cancer
11.7.6. Prostate Cancer
11.7.7. Others
11.7.8. Infectious Diseases
11.7.9. Cardiovascular Diseases
11.7.10. Central Nervous System Disorders
11.7.11. Immunolo
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Pharmaceuticals Demand Share Forecast, 2019-2026
12. Middle East & Africa Pharmaceuticals Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Pharmaceuticals Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Pharmaceuticals Market Size and Volume Forecast by Types
12.4.1. Branded
12.4.2. Generics
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Pharmaceuticals Market Size and Volume Forecast by Applications
12.7.1. Oncology
12.7.2. Breast Cancer
12.7.3. Lung Cancer
12.7.4. Colorectal Cancer
12.7.5. Ovarian Cancer
12.7.6. Prostate Cancer
12.7.7. Others
12.7.8. Infectious Diseases
12.7.9. Cardiovascular Diseases
12.7.10. Central Nervous System Disorders
12.7.11. Immunolo
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Pharmaceuticals Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Pharmaceuticals Market: Market Share Analysis
13.2. Pharmaceuticals Distributors and Customers
13.3. Pharmaceuticals Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Boehringer Ingelheim International GmbH
13.4.2. Bayer AG
13.4.3. Merck & Co Inc
13.4.4. Fresenius Kabi AG
13.4.5. STADA Arzneimittel AG
13.4.6. Pfizer Inc
13.4.7. Abbott Laboratories
13.4.8. Abbvie Inc
13.4.9. Teva Pharmaceuticals Industries Ltd
13.4.10. Novartis AG
Our Clients
Related Reports
Some other reports from this category!
